Negligible influence of comorbidity on prognosis of patients with small cell lung cancer: A population-based study in the Netherlands

被引:32
作者
Janssen-Heijnen, M. L. G.
Lemmens, V. E. P. P.
van den Borne, B. E. E. M.
Biesma, B.
Oei, S. B.
Coebergh, J. W. W.
机构
[1] Ctr Comprehens Canc, Eindhoven Canc Reg, NL-5600 AE Eindhoven, Netherlands
[2] Catharina Hosp, Dept Pulm Dis, NL-5602 ZA Eindhoven, Netherlands
[3] Jeroen Bosch Hosp, Dept Pulm Dis, NL-5200 ME sHertogenbosch, Netherlands
[4] Dr Bernard Verbeeten Inst, Dept Radiat Oncol, NL-5000 LA Tilburg, Netherlands
[5] Erasmus Univ, Ctr Med, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands
关键词
comorbidity; side effects of treatment; elderly; population-based; prognosis; small cell lung cancer;
D O I
10.1016/j.critrevonc.2006.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Management of small cell lung cancer (SCLC) among elderly is complex because of decreased organ functions and interactions with comorbidity. Since elderly patients are often excluded from clinical trials, little is known about the way they are treated and outcome. We evaluated the prognostic effects of rising age and comorbidity in unselected Dutch SCLC patients (Eindhoven Cancer Registry). Elderly patients received chemotherapy less often and the dose was also reduced more often. Cardiovascular diseases, hypertension or diabetes lowered the proportion receiving combined chemotherapy and radiotherapy among patients with limited disease. About 80% of the patients receiving chemotherapy suffered from a side effect, which was not related to age. After adjustment for age, gender, stage and treatment modality, comorbidity had a negligible prognostic effect. Chemotherapy (in combination with radiotherapy) seemed to improve survival, however, toxicity and quality of life in these patients should be evaluated thoroughly in future randomized studies. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:172 / 178
页数:7
相关论文
共 37 条
[1]   DETERMINANTS OF IMPROVED OUTCOME IN SMALL-CELL LUNG-CANCER - AN ANALYSIS OF THE 2,580-PATIENT SOUTHWEST ONCOLOGY GROUP DATA-BASE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1563-1574
[2]  
ARRIAGADA R, 1994, ANTICANCER RES, V14, P333
[3]   Age and the treatment of lung cancer [J].
Brown, JS ;
Eraut, D ;
Trask, C ;
Davison, AG .
THORAX, 1996, 51 (06) :564-568
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]  
Dajczman E, 1996, CANCER, V77, P2032, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2032::AID-CNCR10>3.3.CO
[6]  
2-Q
[7]   Influence of age and comorbidities on the chemotherapeutic management of lung cancer [J].
Deppermann, KM .
LUNG CANCER, 2001, 33 :S115-S120
[8]  
deRijke JM, 1996, ANN ONCOL, V7, P677
[9]   Management of small-cell lung cancer in the elderly [J].
Gridelli, C ;
De Vivo, R ;
Monfardini, S .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 41 (01) :79-88
[10]   Underrepresentation of patients 65 years of age or older in cancer-treatment trials. [J].
Hutchins, LF ;
Unger, JM ;
Crowley, JJ ;
Coltman, CA ;
Albain, KS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (27) :2061-2067